Expertise in
22
conditions

Dr. Ashok B. Raj

Hematology | Oncology
Norton Children's Sleep Medicine-Novak Center
411 E Chestnut St, 
Louisville, KY 
Clinical Trials:Currently Recruiting for 6 Trials
Accepting New Patients
Expertise in
22
conditions
Norton Children's Sleep Medicine-Novak Center
411 E Chestnut St, 
Louisville, KY 

Overview

Ashok Raj is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky.

Dr. Raj is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobin SC Disease, Immune Thrombocytopenic Purpura (ITP), Bone Marrow Aspiration, and Lithotripsy.

He is actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 60 clinical trials. Dr. Raj is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatrics in KY

Hospital Affiliations

Huntington Hospital

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Norton Children's Sleep Medicine-Novak Center
411 E Chestnut St, Louisville, KY 40202

Additional Areas of Focus

Dr. Raj has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

60 Clinical Trials

A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Newly Diagnosed High-Risk Neuroblastoma
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Newly Diagnosed High-Risk Neuroblastoma
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Drug
Study Drugs: Ceritinib, Dasatinib, Sorafenib, Vorinostat, DFMO
Study Phase: Phase 2
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2026
Intervention Type: Drug
Study Drug: Difluoromethylornithine (DFMO)
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
View 4 Less Clinical Trials

44 Total Publications

Improved prognostic survival models for pediatric medulloblastoma using high dimensional gene expression data.
Improved prognostic survival models for pediatric medulloblastoma using high dimensional gene expression data.
Journal: BMC medical genomics
Published: January 11, 2026
Similar Doctors
Expertise in
59
conditions
Dr. Michael D. Kommor
Hematology | Oncology
Expertise in
59
conditions
Dr. Michael D. Kommor
Hematology | Oncology
Referral may be required

Baptist Health Lagrange Kresge Pharmacy

4003 Kresge Way Ste 500, 
Louisville, KY 
 (5.0 miles away)
502-897-1166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Kommor is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky. Dr. Kommor is highly rated in 59 conditions, according to our data. His clinical expertise encompasses Splenic Neoplasm, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Lung Cancer. Dr. Kommor is currently accepting new patients.

Expertise in
45
conditions
Dr. Udaya G. Joseph
Hematology | Oncology
Expertise in
45
conditions
Dr. Udaya G. Joseph
Hematology | Oncology
Referral may be required

Baptist Health Lagrange Kresge Pharmacy

4003 Kresge Way Ste 500, 
Louisville, KY 
 (5.0 miles away)
502-897-1166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Udaya Joseph is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky. Dr. Joseph is highly rated in 45 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Myelodysplastic Syndrome (MDS), and Inflammatory Breast Cancer. Dr. Joseph is currently accepting new patients.

Expertise in
52
conditions
Dr. John L. Huber
Hematology | Oncology
Expertise in
52
conditions
Dr. John L. Huber
Hematology | Oncology
Referral may be required

Baptist Health Lagrange Kresge Pharmacy

4003 Kresge Way Ste 500, 
Louisville, KY 
 (5.0 miles away)
502-897-1166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Huber is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky. Dr. Huber is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Chronic Lymphocytic Leukemia (CLL), Thrombocytopenia, and Bone Marrow Aspiration. Dr. Huber is currently accepting new patients.

Frequently Asked Questions about Dr. Ashok B. Raj

How do I make an appointment with Dr. Ashok B. Raj?

You can book an appointment with Dr. Ashok B. Raj by calling their office at 502-588-3600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ashok B. Raj a top-rated expert for Sickle Cell Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ashok B. Raj is classified as an Distinguished expert for Sickle Cell Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ashok B. Raj specialize in?

While Dr. Ashok B. Raj is a Hematology, they have specific expertise in Sickle Cell Disease, Hemoglobin SC Disease, and Immune Thrombocytopenic Purpura (ITP). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ashok B. Raj participate in research or clinical trials?

Yes. Dr. Ashok B. Raj has published 44 articles and abstracts on conditions like Sickle Cell Disease. You can view a list of Dr. Ashok B. Raj's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ashok B. Raj accept my insurance?

Dr. Ashok B. Raj accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 502-588-3600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Raj's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile